

NEWS RELEASE

iX Biopharma Reports Robust FY2025 Performance with 30% Revenue Growth and Margin Expansion

- ✓ **30% Increase in Sales**
- ✓ **95% Increase in Gross Profit**
- ✓ **\$1.6 Million Reduction in Adjusted EBITDA Loss**

Singapore, 29 August 2025 – iX Biopharma Ltd (SGX: 42C) is pleased to announce its unaudited financial results for the year ended 30 June 2025, delivering strong revenue growth, improved margins, and reduced adjusted EBITDA losses, underscoring the Group's resilience and disciplined execution.

Financial Highlights:

- **Revenue growth:** Total revenue increased **30% year-on-year** to \$7.77 million.
- **Gross profit expansion:** Gross profit nearly doubled, **rising 95%** to \$2.04 million, with gross margin **improving to 26%** for FY2025 (2H25: 30%).
- **Cost discipline:** Adjusted EBITDA loss of reportable segments **narrowed by \$1.6 million** to \$2.2 million, reflecting operational efficiencies and cost savings.
- **Strong cashflow management:** Net cash used in operating activities **reduced by \$2.8 million** compared to FY2024.

Commentary

FY2025 was a transformative year for iX Biopharma, marked by revenue growth across both Specialty Pharmaceuticals and Nutraceuticals.

- **Specialty Pharmaceuticals:** Revenue grew 22%, driven by strong demand for medicinal cannabis products and services in Australia. Adjusted EBITDA losses narrowed significantly from \$2.2 million in FY2024 to \$1.5 million in FY2025.
- **Nutraceuticals:** Revenue more than doubled for the year and rose fourfold in 2H25, with new engagements in the PRC, USA, Europe, and the Middle East. SL-NAD+ was a key growth driver, contributing over 75% of new sales. Segment EBITDA losses were halved from \$1.6 million to \$0.8 million.

Gross profit gains were supported by higher throughput, operating leverage and the successful rollout of new higher-dosage formulations of LumeniX and SL-NAD+.

With iX Biopharma prioritizing the commercialization of its drug and nutraceutical assets, the Group realigned its cost structure and calibrated its expenses, resulting in an overall cost saving of \$1.20 million or 12% compared to FY2024. Together with strong revenue growth and economies of scale,

these efforts narrowed adjusted EBITDA losses of reportable segments from \$3.8 million in FY2024 to \$2.2 million in FY2025. A \$2.8 million reduction in net cash used in operations from \$6.6 million in FY2024 to \$3.8 million reflects stronger cash discipline.

Outlook

Looking ahead, iX Biopharma will focus on scaling its wellness business, with SL-NAD+ leading entry into the fast-growing U.S. longevity market. In parallel, the Group will monetise its pharmaceutical pipeline through partnerships with U.S. compounding pharmacies, leveraging its proprietary sublingual formulations to accelerate speed to market and create future licensing opportunities.

Despite macroeconomic headwinds, the Group's asset-light model and dual-engine strategy across nutraceuticals and pharmaceuticals position it well to continue to grow and deliver sustainable value.

Note: This media release is to be read in conjunction with the announcement issued on SGXNET on the same date.

About iX Biopharma Ltd

iX Biopharma Ltd (SGX: 42C) is a specialty pharmaceutical and nutraceutical company focused on the development and commercialisation of innovative therapies using its proprietary wafer-based drug delivery technologies. The Group operates a fully integrated business model with R&D and manufacturing in Australia and is listed on the Catalist board of the Singapore Exchange.

The Company is strategically scaling its **wellness portfolio** led by its proprietary SL-NAD+ wafer for longevity and healthy aging while pursuing commercialisation of its pharmaceutical pipeline through compounding pharmacy channels in the United States. This approach delivers near-term cashflow and shifts the focus away from long-cycle traditional drug development.

Its proprietary sublingual platforms, **WaferiX™** and **WaferlogiX™**, share a highly porous, amorphous, non-ionic matrix that enables rapid disintegration, superior absorption and predictable clinical outcomes. WaferiX™ has been proven across small molecules and nutraceuticals, while WaferlogiX™ extends the technology to biologics, opening opportunities in compounding and potential out-licensing in high-value therapeutic areas such as diabetes and weight loss.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Daniel Chow
Director of Business Development
T: +65 6235 2270
E: daniel.chow@ixbiopharma.com